عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Media Minister: Saudi History Exhibition Establishes Relationship between Saudi Media, National History

Minister of Media Salman bin Yousef Al-Dosari at the exhibition. SPA
Minister of Media Salman bin Yousef Al-Dosari at the exhibition. SPA
TT
TT

Media Minister: Saudi History Exhibition Establishes Relationship between Saudi Media, National History

Minister of Media Salman bin Yousef Al-Dosari at the exhibition. SPA
Minister of Media Salman bin Yousef Al-Dosari at the exhibition. SPA

The Minister of Media and Chairman of the Board of Directors of the Saudi Press Agency (SPA), Salman bin Yousef Al-Dosari, expressed the Saudi media’s pride in its national message and its responsibility to consolidate the historical depth of the Saudi state by introducing its achievements, nobility, and cultural and social heritage, and promoting its civilizational achievement and regional and global status so that the progress march continues towards a promising future for the nation and the citizens under the Saudi Vision 2030.

He made his remarks following the opening on Wednesday of “Saudi Arabia's History Exhibition” at the headquarters of SPA in Riyadh. He noted that this documentary initiative aims to enrich historical knowledge and highlights the prosperous present of the country, within a framework that reflects the image of the Kingdom on the world stage.

He added that SPA’s holding of an exhibition on Saudi Arabia's history comes in the context of its national media role and to enrich its educational and knowledgeable message through an interactive media presentation, in a new experience for visitors from inside and outside the Kingdom, applying an innovative method that establishes a relationship between the media institution and the Kingdom's history.

The minister of media reiterated that the exhibition embodies the depth of the media’s connection with Saudi Arabia's history.

Nearly a century ago, the Kingdom witnessed the publication of Umm Al-Qura newspaper in 1924, in which it documented events and the reality of the national scene in its various aspects then. The issue of September 23, 1932 announced the declaration of all parts of the Kingdom united, under the name "Kingdom of Saudi Arabia,” marking a new era of development and modernization of the media sector, the diversity of its mass-media organizations, and the breadth of its message, keeping pace with the latest technologies across various media platforms.

After his statement, the minister of media extended his thanks and appreciation to the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz Al Saud, and Prince Mohammed bin Salman bin Abdulaziz, Crown Prince and Prime Minister, for their support to Saudi media, and their continued interest in developing it, to enhance its role in highlighting the Kingdom's movement, under the goals of Saudi Vision 2030.

Most Viewed

 
 
Varieties

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”